Your Search Returned 145 tagged news reports
Wall Street sell-off, as Arm leads technology stocks lower Worries about global growth unsettle investors but cement deal lifts CRH A sharp sell-off on Wall Street late last week has spilled over into Asian markets overnight and into early trading in
R Pfizer has announced that the US Food and Drug Administration (FDA) has approved the over-the-counter drug Nexium 24HR (esomeprazole 20mg), which is indicated to treat the symptoms of acid reflux disease, which typically include persistent
Receives Another Breakthrough Therapy Status for a Drug Pfizer Inc. ( PFE ) announced yesterday that the Food and Drug Administration (FDA) had given its investigational vaccine bivalent rLP2086 breakthrough therapy designation. The vaccine is being
AZN The thing about technological and scientific change is that it can happen very quickly. University start-ups can be transformed into global titans think of Facebook . And internationally known giants can end up in the bankruptcy courts think of
February 15, 2014 A 50-year-old man is evaluated for persistent heartburn and regurgitation despite taking a high-dose proton-pump inhibitor twice a day for 6 months. His symptoms have improved, but he continues to have symptoms many times a week...
Drugmaker AstraZeneca has showed it is still languishing in intensive care after patent expiries triggered an 8 per per cent fall in sales to $25.7 Despite new chief executive Pascal Soriot's recent string of acquisitions to boost Astra's pipeline,
Big pharma stocks have surged behind the market's rally, but that doesn't mean that every company in this top health care industry's performing up to healthy standards. Between the patent cliff and the latest China bribery scandal, several top
Our first story today involves Nestle, the Swiss company which is commonly associated with snacks and drinks. Yesterday, the Wall Street Journal reported that Nestle is working out a surprising deal with Cellular Dynamics International to obtain stem
Endoscopies were performed at baseline and at one, three and six months.
Just 18 months ago, Bristol-Myers Squibb expanded its diabetes franchise by paying $7 billion for Amylin Pharmaceuticals and, simultaneously, broadened a joint venture with AstraZeneca. Now, though, Bristol-Myers is selling its stake in the